309 related articles for article (PubMed ID: 1720485)
1. First clinical experience with isradipine in the treatment of hypertension in Portugal.
Rocha-Gonçalves F; Mariano-Pego G; Viegas J; Correia JM; Botelho MA
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S4-6. PubMed ID: 1720485
[TBL] [Abstract][Full Text] [Related]
2. Calcium antagonists as first-line antihypertensive agents: a placebo-controlled, comparative trial of isradipine and nifedipine.
Welzel D; Burger KJ; Weidinger G
J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S70-4. PubMed ID: 1695308
[TBL] [Abstract][Full Text] [Related]
3. Calcium antagonists as first-line therapy in hypertension: results of the Swiss Isradipine Study. Swiss Hypertension Society.
Lüscher TF; Waeber B
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S1-3. PubMed ID: 1720476
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients.
Batlouni M; Armaganijan D; Ghorayeb N; Magliano MF
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S53-7. PubMed ID: 1376836
[TBL] [Abstract][Full Text] [Related]
5. Isradipine in the treatment of mild-to-moderate hypertension in Portugal.
Pereira-Miguel JM; Correa-Nunes A; Rocha-Gonçalves F; Mariano-Pego G
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S49-52. PubMed ID: 1376835
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of isradipine and captopril alone or in combination for the treatment of hypertension.
Fitscha P; Meisner W; Hitzenberger G
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S12-4. PubMed ID: 1720478
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension.
Kirch W; Burger KJ; Weidinger G; Welzel D
J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S55-9. PubMed ID: 1695304
[TBL] [Abstract][Full Text] [Related]
8. Clinical studies on isradipine in the management of adult hypertensive patients at Moi University Teaching Hospital, Eldoret, Kenya.
Lore W; Anjichi GM
East Afr Med J; 1992 Feb; 69(2):69-73. PubMed ID: 1387077
[TBL] [Abstract][Full Text] [Related]
9. The antihypertensive action of isradipine in mild essential hypertension.
Viskoper JR; Laszt A; Farragi D
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S9-11. PubMed ID: 1720488
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of isradipine in the treatment of mild-to-moderate hypertension in general practice: a large-scale surveillance study.
Hermans L; Bogaert M; Degaute JP; Rorive G; Six R; Bara L; Lanssiers P; De Keyser P; Westelinck KJ
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S38-45. PubMed ID: 1376833
[TBL] [Abstract][Full Text] [Related]
11. [Antihypertensive effect and adverse effects of isradipine in patients with sever hypertension. Results of an open multicenter study].
Burger KJ; Dehner R
Arzneimittelforschung; 1996 Jun; 46(6):600-5. PubMed ID: 8767350
[TBL] [Abstract][Full Text] [Related]
12. The use of calcium antagonists to treat intra-operative hypertension--evaluation of efficacy and safety of a new dihydropyridine derivative, intravenous isradipine, during abdominal surgery.
Edouard A; Dartayet B; Ruegg C; Samii K
Eur J Anaesthesiol; 1991 Sep; 8(5):351-8. PubMed ID: 1834462
[TBL] [Abstract][Full Text] [Related]
13. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
[TBL] [Abstract][Full Text] [Related]
14. Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group.
Jern S; Hansson L; Scherstén B; Kullman S; Sörensen S; Dahlöf B; Eggertsen R; Sivertsson R
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S7-8. PubMed ID: 1720487
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
[TBL] [Abstract][Full Text] [Related]
16. A double-blind comparison of the efficacy and safety of lacidipine with atenolol in the treatment of essential hypertension. The United Kingdom Lacidipine Study Group.
J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S27-30. PubMed ID: 1726002
[TBL] [Abstract][Full Text] [Related]
17. Metabolic, hematological, and cardiac effects of long-term isradipine treatment in mild-to-moderate essential hypertension.
Meriç M; Gören T; Atilgan D; Eren N; Cubukçu A; Koylan N
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S58-60. PubMed ID: 1376837
[TBL] [Abstract][Full Text] [Related]
18. [Circadian antihypertensive effect of sustained-release isradipine in patients with essential hypertension in comparison to placebo].
Burger KJ; Anlauf M
Arzneimittelforschung; 1993 Sep; 43(9):958-62. PubMed ID: 8240458
[TBL] [Abstract][Full Text] [Related]
19. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
20. Clinical equivalence of once-daily administration of a modified-release formulation of isradipine and twice-daily administration of the standard formulation. Multicentre Study Group.
Holmes D; Moullet C
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S61-5. PubMed ID: 1376839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
